AUSTIN, Texas, June 28, 2022–(BUSINESS WIRE)–Texas Original, Texas’ leading medical cannabis provider, announced its newest prescription pickup location has opened in Waco, Texas. The new location is Waco’s first medical cannabis pickup site and the first drive-thru location in the state. The pickup location is open every Friday between 10:30 a.m. and 2 p.m. for patients who qualify under the Compassionate Use Program.

Texas Original operates the most robust medical cannabis distribution network in Texas. In addition to its convenient pickup locations open weekly throughout the state, the company also delivers prescriptions directly to patients’ doorsteps on a daily and weekly basis. The Waco opening marks another important milestone in the company’s pursuit of expanding access to life-changing medical cannabis treatment for every Texan. Waco-area patients like Barry Freeman—who uses medical cannabis to treat symptoms of PTSD—now have a convenient option to pick up their prescriptions locally.

“Medical cannabis has helped me sleep better, live without the burden of chronic pain and eliminate pain pills from my treatment,” Freeman said. “Texas Original’s medicine has changed my life and I’m so grateful to have nearby access to their products through the Waco pickup location.”

Registered physicians can prescribe medical cannabis to treat conditions including epilepsy, cancer, PTSD and hundreds of neurodegenerative disorders. Texas Original’s medicine alleviates common symptoms—including chronic pain, insomnia and anxiety—associated with such conditions for thousands of patients. Qualifying Waco residents can obtain medical cannabis prescriptions through online clinics or Waco-based physicians registered with the Compassionate Use Registry of Texas.

“Getting your medical cannabis prescription filled should be as easy as picking up any other medicine,” said Morris Denton, CEO of Texas Original. “Swiftly receiving care from the comfort of your car is another significant step toward expanding access for our patients. I encourage Waco residents to ask their doctors about the life-changing benefits of medical cannabis and reach out to us to start experiencing relief as soon as possible.”

Waco patients can continue to access their prescriptions through Texas Original’s delivery network. Today’s announcement also follows the opening of Texas Original’s first permanent medical cannabis pickup location in Houston, which serves the greater Houston area five days a week. Operating times for the company’s permanent Houston Heights location and other local pickup sites can be found on the Texas Original website here.

Texas Original’s suite of gummies, tincture and lozenge products are also available for pickup at the company’s dispensary in Austin, Texas. To learn whether you or a loved one qualifies for medical cannabis, visit www.texasoriginal.com/patients.

About Texas Original

Texas Original is the leading licensed medical cannabis producer in Texas, working alongside physicians to provide the highest quality cannabis medicine to patients and families seeking relief across the state. As fellow Texans, we are dedicated to representing the integrity of this great state with our commitment to quality, consistency and purity in every product we produce. We remain committed to advancing safe, legal access to this powerful medicine. Texas Original is headquartered in Austin, with delivery throughout the entire state. For more information, visit www.texasoriginal.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

AUSTIN, Texas, May 24, 2022–(BUSINESS WIRE)–Texas Original Compassionate Cultivation’s (TXOG) new 10-count package of fast-acting gummies will be available beginning Tuesday, May 31, 2022. For $35, patients can access 100 mg of Texas’ highest quality medical cannabis in an on-the-go package designed to make treatment flexible. Qualifying patients can preorder the product starting today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005286/en/

Texas Original’s new 10-count package of fast-acting gummies will be available beginning Tuesday, May 31, 2022. (Photo: Business Wire)

The condensed package of TXOG’s popular gummies will come in THC-only (10 mg of THC per gummy) or balanced CBD to THC (5 mg of CBD and 5 mg of THC per gummy) formulations. Each formulation is available in sour peach mango or strawberry passion fruit flavors. Patients can now test smaller quantities of TXOG’s gummies—at a convenient price point—in various flavors and formulations before deciding with their physician the medication best for them.

“Accessing medical cannabis through the Compassionate Use Program should be easy and affordable,” said Morris Denton, CEO of TXOG. “The combined cost of doctor visits and medicine can make participating in the CUP financially difficult for many Texans. Our team is dedicated to meeting patients where they are, whether financially or physically, with the products they trust. That means working closely with physicians to reduce costs where possible. We’ve also built the state’s most robust medical cannabis delivery and distribution program. Now, patients can try our medicine and experience its life-changing benefits with our 10-count pack of gummies before committing to more.”

TXOG’s gummy, tincture and lozenge products are available for statewide delivery, for pick-up at TXOG’s dispensary in Austin, Texas, and through the company’s convenient pick-up locations in Addison, Corpus Christi, Dallas, El Paso, Fort Worth, Houston, Lubbock, North Austin, San Antonio and Wichita Falls.

Learn whether you or a loved one qualifies for medical cannabis at www.texasoriginal.com/patients.

About Texas Original Compassionate Cultivation

Texas Original Compassionate Cultivation (TXOG) is the leading licensed medical marijuana producer in Texas, working alongside physicians to provide the highest quality cannabis medicine to patients and families seeking relief across the state. As fellow Texans, we are dedicated to representing the integrity of this great state with our commitment to quality, consistency and purity in every product we produce. We remain committed to advancing safe, legal access to this powerful medicine. TXOG is headquartered in Austin, with delivery throughout the entire state. For more information, visit www.texasoriginal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005286/en/

Contacts

Emma Chase
[email protected]
512-917-4319

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

This is the first step in a series of launches with a variety of supermarkets in the US.

MONTREAL, April 13, 2022 /CNW/ – The Good Shroom Co Inc. (the “Company” or “MUSH“) (TSXV: MUSH), executes its first large retailer launch.

MUSH, through its licensed subsidiary Teonan Biomedical Inc., operates Teonan instant wellness beverages. In line with its retail strategy, MUSH is pleased to announce that it is launching in all Central Market locations.

Central Market is one of many key targets for Teonan due to its customer base which is health conscious and generally purchase clean label products. It is a higher end supermarket chain in the organic/healthy segment with 10 large locations. Its US sales and marketing team are working alongside Central Market to assure proper shelf positioning and visibility of all the Teonan products.

The approval of Central Market is not only a win for the Teonan brand but also sets precedent for a variety of other similar retailers.

MUSH CEO Eric Ronsse stated “The health food industry is ripe for disruption. It has more health conscious consumers than ever before. It doesn’t just take a great product at a good price to succeed. You need large scale distribution, merchandizing and a solid sales team in order to obtain large early adopter retail accounts. This is why we are pleased to announce our launch in Central Market. We expect this will be the first of many.”

www.thegoodshroom.co
www.teonan.com
www.nordiqueroyale.ca
www.velada.ca

About the Company

MUSH operates a portfolio of brands which include traditional cannabis and beverage products. It exists to promote the use of functional ingredients such as probiotics and functional mushrooms in consumer products. Its line of Teonan beverages are first a quality and tasty beverage but also contain a dose of functional mushrooms and probiotics.

We all have a daily routine; be it coffee, tea or another. Why not make that routine functional for body and mind by adding probiotics and mushrooms to it? Up to now no company has been able to maintain a familiar taste at a fair price while making them truly functional. The Good Shroom Co has bridged that gap and intends on making its brands household names for making it a part of its customers daily routine.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Corporation with respect to future business activities and sales, including the anticipated orders to be placed by the SQDC. Forward-looking statements are often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions. Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect the Corporation’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Corporation believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected are the following: market acceptance of the Company’s hash and other cannabis products, changes in the vendor’s business or strategy, changes in our supplier’s operations and pricing, expectations regarding competition and their pricing strategy; maintaining in good standing all necessary regulatory licenses and authorizations for its products; the benefits, safety, efficacy, dosing and social acceptance of cannabis related products and no material changes in the legal environment; changes in applicable laws and regulations compliance with extensive government regulation; operational risks related to and COVID-19 or other pandemic and supply chain disruptions and shortages. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. The Company does not intend, and do not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law. Trading in the securities of the Company should be considered highly speculative.

SOURCE The Good Shroom Co Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

SEATTLE, March 22, 2022–(BUSINESS WIRE)–POSaBIT Systems Corporation (CSE: PBIT, OTC: POSAF), the leading provider of point of sale software and payments infrastructure in the cannabis industry, has launched their point of sale and payments solution in two new markets: Texas and Georgia. These are the seventeenth and eighteenth states overall where a POSaBIT solution is active.

“As a company, we remain focused on expanding our geographical reach, and our entry into Texas and Georgia reflects both the hard work of our team and the overall reputation of our point of sale solution within the cannabis industry,” said Ryan Hamlin, CEO and Co-founder of POSaBIT. “Our ability to serve any and all viable markets is a key proof point in our path towards exponential growth and scalability.”

POSaBIT is now active in 18 states across the country and will aim to enter a handful of additional markets over the remainder of 2022 and beyond.

About POSaBIT

POSaBIT (CSE: PBIT) is a financial technology company that delivers unique and innovative payment processing and point-of-sale systems for cash-only businesses. POSaBIT specializes in resolving pain points for complex, high-risk, emerging industries like cannabis with an all-in-one solution that is compliant, user-friendly, and utilizes top-of-the-line hardware. POSaBIT’s unique solution provides a safe and transparent environment for merchants while creating a better overall experience for the consumer. For additional information, visit www.posabit.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding our business strategy, product development, timing of product development, events and courses of action.

Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggesting future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated cash needs and our estimates regarding our capital requirements and our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing products; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which POSaBIT will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements

Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely affect our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; market conditions and the demand and pricing for our products; our relationships with our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; our ability to manage risks inherent in foreign operations; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; and our dependence on key personnel. POSaBIT is an early stage company with a short operating history; it may not achieve profitability; and it may not actually achieve its plans, projections, or expectations.

Important factors that could cause actual results to differ materially from POSaBIT’s expectations include consumer sentiment towards POSaBIT’s products and blockchain/cryptocurrency exchange technology generally, litigation, global economic climate, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, and failure of counterparties to perform their contractual obligations.

Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this news release. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise resulting from the use of the information in this news release or for omissions from the information in this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005281/en/

Contacts

Investor Relations:
[email protected]

Media Relations:
Oscar Dahl
855-767-2248
[email protected]

Management:
Ryan Hamlin
Co-founder and CEO of POSaBIT
855-767-2248
[email protected]

Hayden IR
James Carbonara
(646) 755-7412
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety

VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”), developer of marijuana breathalyzer devices for law enforcement and the workplace, reports that it will be presenting at the Texas Impaired Driving Forum, held by Texas A&M Transportation Institute (TTI) in February. Cannabix’s Dr. Jared Boock, Ph.D., will be presenting the Company’s marijuana breathalyzer technologies and approaches at the Forum. The 2021 Texas Impaired Driving Forum attracted approximately 300 attendees from across the state of Texas. These traffic safety stakeholders specialize in fields such as prosecution, judicial review, probation, law enforcement, education/advocacy, prevention, treatment, and highway safety.

THCBA update

The Company reports that the version 4.0 THC Breath Analyzer (“THCBA”) sensor apparatus for production is being bench tested with preliminary standardized testing showing that this updated design results in less than half of the standard deviation variability of the successful previous version 3.0 sensor. This updated sensor apparatus design and related hardware improvements have been developed incorporating feedback from beta-test users as well as planned design changes which have been prepared over the past months. Several components such as the device’s internal sampling chambers, microfluidic sensors and related actuation mechanism have been simplified to minimize manufacturing variability and to reduce cost. The first fully assembled version 4.0 THCBA devices for human testing are on track for December – this will be followed by broad field testing and clinical testing to establish V4.0 benchmark standards.

The THCBA is a drug screening device for various markets who are seeking a way to quickly (in less than 5 minutes), easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment. The THCBA consists of a handheld device and protective case which houses a sterilization module, sample preparation stage, device recovery station and integrated battery charging system.

Germany

Recently, the leaders of all three parties that make up the German coalition government entered into a four-year coalition agreement that sets out a commitment to “introduce the controlled distribution of cannabis to adults for recreation.” With a population of over 83 million, Germany could be become one of the largest legal cannabis markets in the world. The Company reports that it has been in discussions with companies in Germany for the advancement of Cannabix marijuana breath testing tools and may allocate resources as necessary to take advantage of these opportunities.

Dr. Richard Yost

Dr. Richard Yost (Ph.D.) of the University of Florida (UF) has entered into a consulting agreement with the Company as well as maintaining his role as Senior Scientific Advisor in the area of FAIMS technology development. Dr. Yost is the winner of the Pittsburgh (Pittcon) Analytical Chemistry Award for 2021. Dr. Yost is widely recognized as a world leader in the field of mass spectrometry and analytical chemistry, most notably for his co-invention of the triple quadrupole mass spectrometer, which has revolutionized important measurements impacting human health and well-being in the fields of drug metabolism, pharmacokinetics, environmental studies, and biological analyses. The consulting agreement with Dr. Yost has been adopted, as the Company’s research term with UF has ended.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC – the psychoactive component of marijuana that causes impairment – using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix devices are in the advanced prototype and pre-clinical testing stage.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at [email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of marijuana breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness ” or the “ Company ”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, today announced a $3 million national distribution agreement with Texas-based distribution and advertising company One Light Enterprises LLC. (“ One Light ”) for Silo Wellness’ portfolio of Marley One branded mushroom products across 47 U.S. states (the “ Distribution Agreement ”).

Today’s announcement comes on the heels of Silo Wellness’ U.K. distribution agreement with LocoSoco Group PLC, announced earlier this month. Together with the Distribution Agreement, Silo Wellness has cemented strong routes to market in both the U.S. and the U.K. for its Marley One global mushroom brand, created in collaboration with the family of legendary musician Bob Marley.

“We have seen tremendous consumer interest in the Marley One brand, and we are pleased to announce a distribution partner for the all-important U.S. market,” said Douglas K. Gordon, Chief Executive Officer, Silo Wellness. “One Light is a respected and like-minded partner who shares our vision for Marley One and our commitment to delivering best-in-class consumer experiences and products.”

One Light will distribute the full line of Marley One mushroom products, beginning with the brand’s initial five functional mushroom tinctures, to retailers across the U.S. Silo Wellness also intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules, and cosmetics.

“We are excited to partner with Silo Wellness to bring Marley One to U.S. consumers,” said Twin Rivers Group, LLC, Managing Member of One Light. “We partner with some of the best-loved brands in the market today, and we anticipate Marley One will be well-received by consumers, particularly as they seek out natural, plant-based wellness products to enhance their everyday lives.”

According to Mordor Intelligence , the global functional mushroom market was valued at USD 25,415.12 million in 2020, and is estimated to register a CAGR of 8.44% during the forecast period of 2021-2026. Mordor Intelligence also notes that functional mushrooms are expected to have increased applicability beyond healthcare or pharmaceutical products over the long term, particularly in the food and beverage sector.

Corporate Update

On August 11, 2021, the Company entered into a loan agreement with an arm’s length third party lender (the “ Lender ”) pursuant to which the Company borrowed US$250,000 for working capital and inventory growth purposes (the “ Loan ”). Subsequently, the Company entered into a debt settlement agreement with the Lender to settle US$144,000 of the Loan in exchange for 2,500,000 Common Shares at a deemed price of C$0.072 per Common Share, representing a 20% discount to the closing price of the Common Shares on August 11, 2021 (the “ Shares for Debt ”). The remaining principal amount of the Loan remains outstanding. Completion of the Shares for Debt is subject to compliance with applicable regulations, including policies of the CSE.

The Company has agreed to issue Common Shares to two arm’s length service providers in accordance with previously agreed arrangements (the “ Shares for Services ”). Pursuant to various agreement for services, the Company intends to issue an aggregate of 5,310,000 Common Shares with 5,000,000 Common Shares issued at a deemed price of C$0.13 and 310,000 Common Shares issued at a deemed price of C$0.10. Completion of the Shares for Services is subject to compliance with applicable regulations, including policies of the CSE.

The Company also announces that Peter Holzworth, vice president of business development has resigned from his position.

For more information about Silo Wellness, please visit https://www.silowellness.com/ . To buy Marley One products, please visit https://marleyone.com/ .

ABOUT SILO WELLNESS
Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FRA: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.marley.one .

For more information about Silo Wellness, please visit www.silowellness.com .

For further information, please contact:

Silo Wellness Media Relations:
[email protected]

Silo Wellness Investor Relations:
(778) 383-6740
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements”  (collectively, “forward-looking statements”) within the meaning of the applicable Canadian  securities legislation. All statements, other than statements of historical fact, are forward-looking  statements and are based on expectations, estimates, and projections as at the date of this news  release. Any statement that involves discussions with respect to predictions, expectations, beliefs,  plans, projections, objectives, assumptions, future events or performance (often but not always  using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not  anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or  variations of such words and phrases or stating that certain actions, events or results “may” or  “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical  fact and may be forward-looking statements. In this news release, forward-looking statements  relate, among other things, to: the Distribution Agreement the distribution partnership with One Light, the Shares for Debt, the Shares for Services and the business plans of Silo Wellness. Forward-looking statements are  necessarily based upon a number of estimates and assumptions that, while considered  reasonable, are subject to known and unknown risks, uncertainties, and other factors which may  cause the actual results and future events to differ materially from those expressed or implied by  such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19.  There can be no assurance that such statements will prove to be accurate, as actual results and  future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information  contained in this news release. Silo Wellness assumes no obligation to update the forward-looking  statements of beliefs, opinions, projections, or other factors, should they change, except as  required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES  PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS  RELEASE.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>

Launches its goodblend retail brand (Surterra Texas is now goodblend Texas), creates hundreds of new jobs, and positions itself for strategic growth in the Lone Star State

ATLANTA and AUSTIN, Texas, April 19, 2021 /PRNewswire/ — Parallel, one of the largest privately-held multi-state cannabis operators in the United States (U.S.), today announced it will make a $25 million dollar investment in a new state-of-the art cannabis cultivation, production and retail facility in Texas. This financial commitment expands Parallel’s ability to meet the growing patient demand for medical cannabis products in the Lone Star State. The planned 63,000 square-foot facility is expected to create hundreds of new jobs in the San Marcos region.

The company is also introducing its goodblend retail brand, as it is changing the name of Surterra Texas to goodblend Texas (goodblend). This is the second market where Parallel has introduced the goodblend name, joining goodblend Pennsylvania; over time the company will evaluate opportunities to roll-out the brand in its existing markets. The goodblend retail brand reflects Parallel’s intent to lead the way to the future of cannabis by providing its customers a trusted, consistent and seamless way for them to connect and learn, and to access innovative, high-quality cannabis products in a variety of form factors. The brand is about welcoming every type of customer and being an approachable source for our customers’ well-being.

“With our $25 million dollar investment and name change to goodblend, we are strengthening our Texas roots to meet the needs of cannabis patients for the long term. We see high growth potential in the Texas cannabis market as every day more Texans choose cannabis to help improve their quality of life,” said William “Beau” Wrigley Jr., Chairman and CEO for Parallel. “The goodblend brand promise is to make customers feel so good about their experience that they come back again and again. The ethos of goodblend is based on Parallel’s commitment to compliance, quality, consistency and innovation, and on our actions to improve diversity, inclusivity and economic empowerment in the cannabis industry and to be a great employer and local community partner.”

Texas, one of the most populous states in the U.S., with nearly 30 million residents, created the Texas Compassionate Use Program in 2015, providing medical cannabis to qualifying patients.  Parallel’s goodblend retail brand (formerly Surterra Texas) provides patients access to high-quality cannabis products in a variety of form factors that are cultivated and produced locally in Texas to ensure the most consistent patient experience. It was the first cannabis operator in the state to offer patients medical cannabis in gummy and lozenge formats.

“We are thrilled to break ground today on our new facility in San Marcos. We look forward to creating economic empowerment opportunities in this community through new jobs and cannabis career-building programs,” said Marcus Ruark, President of goodblend Texas. “We are encouraged that there is a growing recognition, trust and demand for our medical cannabis products in Texas. While our customers will now know us as goodblend Texas, we will continue to offer registered patients with the state’s largest assortment of cannabis-based product formats.”

Medical cannabis patients across Texas already registered in the program, and those interested in learning more about cannabis, can access board certified prescribers, medical cannabis information, services, and products in the following ways:

• The goodblend Virtual Clinic is a service in which prospective patients can schedule consultations with a board-certified prescriber through a seamless experience. To get started, visittx.goodblend.com/clinic.
• goodblend.com offers a wide variety of products, easy online ordering, and free contactless home delivery, often in as little as three days.
• goodblend’s partner clinics in Plano, Houston, Fort Worth, and San Antonio, provide registered patients a convenient way to pick up goodblend cannabis products at locations in major metropolitan areas.

Commitment to Social Equity 

Parallel is committed to advancing social equity through meaningful actions and partnerships that positively impact the communities in which it has operations, as well as the industry at large. Parallel has partnered with many industry advocacy organizations, including Minority Cannabis Business Association (MCBA), Cannaclusive, CultivatED, and CannabisLAB to drive their shared missions forward and to continue to address diversity and inclusion in the industry. To date, Parallel has focused its efforts across all markets on economic and job empowerment, and diversity and inclusion in the industry through job fairs, skills-building training and seminars, fellowships, and social equity grants, among other actions. Parallel is committed to increasing its diverse 1,700-person workforce, which is currently comprised of well over 30% of minority and female-identifying employees, and 40% of Parallel’s leadership team consists of female and minority representation. Parallel’s proposed slate of seven independent candidates to its public company board of directors, post-closing of the transaction with Ceres, is focused on including at least two female and three BIPOC directors.

About Parallel

Parallel is one of the largest privately-held, vertically integrated, multi-state cannabis companies in the United States with a mission to pioneer well-being and improve the quality of life through cannabinoids. Parallel recently announced that it intends to become a public company through a definitive business combination agreement with Ceres Acquisition Corp. (“Ceres”) (NEO: CERE.U, CERE.WT;OTCQX: CERAF), a special purpose acquisition corporation (SPAC). Parallel has ongoing operations in four medical and adult-use markets under the retail brands of Surterra Wellness in Florida; goodblend in Texas; New England Treatment Access (NETA) in Massachusetts, and The Apothecary Shoppe in Nevada. Parallel also has a license under its goodblend Pennsylvania brand for vertically integrated operations and up to six retail locations, in addition to a medical cannabis research partnership with the University of Pittsburgh School of Medicine. Subject to regulatory approval, Parallel will add Illinois as a sixth market when its recently announced acquisition of six Windy City Cannabis licenses is complete. Parallel has a diverse portfolio of high quality, proprietary and licensed consumer brands and products including Surterra Wellness, Coral Reefer, Float and Heights. Parallel operates approximately 50 locations nationwide, including 42 retail stores, and cultivation and manufacturing sites. Through its wholly-owned Parallel Biosciences subsidiary, it conducts advanced cannabis science and R&D for new product development in its facilities in Massachusetts, Florida, Texas and a facility in Budapest, Hungary through an exclusive license and partnership. Parallel follows rigorous operations and business practices to ensure the quality, safety, consistency and efficacy of its products and is building its business by following strong values and putting the well-being of its customers and employees first. Find more information at www.liveparallel.com, or on Instagram and LinkedIn.

For more information on goodblend Texas and its products, access www.goodblend.com and www.facebook.com/goodblendtx.

Media Contact

Taylor Foxman
[email protected]

Forward Looking Statements

Certain information in this press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation and U.S. securities law (referred to herein as forward-looking statements), including statements regarding the Transaction and expected future growth. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements, which include, but are not limited to, statements related to activities, events or developments that Parallel or Ceres expects or anticipates will or may occur in the future, statements related to Parallel’s business strategy objectives and goals, and Parallel’s management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “should”, “anticipate”, ‘believe”, expect “, “intend”, “potential “, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Such statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and are based on Parallel’s management’s belief or interpretation of information currently available. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements in this press release includes statements regarding: the Transaction; the consummation of the acquisition of Windy City; Parallel’s expansion strategy and plans to grow its market share in existing and new markets, including Illinois; Parallel’s investment in new technologies and products; the development and expansion of Parallel’s brands; and strategic acquisition opportunities. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. There can be no assurance that the transactions described herein will be completed or that, if completed, the combined public company will be successful.

Risk factors that could cause actual results, performance or achievement to differ materially from those indicated in the forward-looking statements include, but are not limited to the following: (i) the risk that the Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Ceres’ securities, (ii) the risk that the Transaction may not be completed by Ceres’ qualifying transaction deadline and the potential failure to obtain an extension of the qualifying transaction deadline if sought by Ceres, (iii) the failure to satisfy the conditions to the consummation of the Transaction, including the approval of the Transaction by the stockholders of Ceres and Parallel, as applicable (iv), the receipt of certain governmental and regulatory approvals, (v) the lack of a third party valuation in determining whether or not to pursue the proposed Transaction, (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vii) the impact of COVID-19 on Parallel’s business and/or the ability of the parties to complete the proposed Transaction, (viii) the effect of the announcement or pendency of the Transaction on Parallel’s business relationships, performance, and business generally, (ix) risks that the proposed Transaction disrupts current plans and operations of Parallel and potential difficulties in Parallel employee retention as a result of the proposed Transaction, (x) the outcome of any legal proceedings that may be instituted against Parallel or Ceres or their respective, directors, officers and affiliates related to the proposed Transaction, (xi) the risk that the combined public company’s securities will not be approved for listing on the NEO Exchange or, if approved, that the combined public company will be able to maintain the listing, (xii) the price of Ceres’ and the combined public company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Parallel operates, variations in performance across competitors, changes in laws and regulations affecting Parallel’s business and changes in the combined capital structure and a return on securities of the combined public company is not guaranteed, (xiii) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed Transaction, and identify and realize additional opportunities, (xiv) the risk of downturns and the possibility of rapid change in the highly competitive industry in which Parallel operates, (xv) the risk that Parallel and its current and future collaborators are unable to successfully develop and commercialize Parallel’s products, brands or services, or experience significant delays in doing so, (xvi) the risk that the combined public company may never sustain profitability, (xvii) the risk that the combined public company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (xviii) the risk that the combined public company experiences difficulties in managing its growth and expanding operations, (xix) the risk that the pharmaceutical industry may attempt to dominate the cannabis industry, and in particular, legal marijuana, through the development and distribution of synthetic products which emulate the effects and treatment of organic marijuana, (xx) the agricultural risks related to insects, plant diseases, unstable growing conditions, water and electricity availability and cost, (xxi) the risk that may arise because cannabis continues to be a controlled substance under the United States Federal Controlled Substances Act, (xxii) the risk of product liability or regulatory lawsuits or proceedings relating to Parallel’s products and services, (xixii) the risk that the combined public company is unable to secure or protect its intellectual property, (xxiv) tax risks, including U.S. federal income tax treatment, (xxv) risks relating to the reliance of Parallel on key members of management, (xxvi) risks inherent in businesses related to the agricultural industry, (xxvii) risks relating to potentially unfavorable publicity or consumer perception, (xxviii) Parallel may be subject to the risk of competition from synthetic production and technological advances, (xxix) investors in the combined public company and its directors, officers and employees who are not U.S. citizens may be denied entry into the United States, (xxx) product recalls, (xxxi) results of future clinical research, (xxxii) difficulty attracting and retaining personnel, (xxxiii) fraudulent or illegal activity by employees, contractors and consultants; information technology systems and cyber-attacks, (xxxiv) security breaches, (xxxv) natural disasters and terrorism risk, (xxxvi) restricted access to banking, (xxxvii) risks related to the lending facilities, (xxxviii) risks of leverage, (xxxix) heightened scrutiny by regulatory authorities, (xI) risk of legal, regulatory or political change, (xli) general regulatory and licensing risks, (xlii) Parallel and the combined public company may be subject to the risk of changes in Canadian as well as U.S. federal, state and local laws or regulations, (xliii) limitations on ownership of licenses, (xliv) Nevada regulatory regime and transfer and grant of licenses, (xIv) regulatory action and approvals from the FDA, (xlvi) constraints on marketing products, (xlvii) anti-money laundering laws and regulation, (xlviii) the combined public company’s status as an “Emerging Growth Company” under United States securities laws, (xlix) discretion in the use of proceeds, (l) subsequent offerings will result in dilution to shareholders of the combined public company, (li) voting control, and (lii) unpredictability caused by capital structure and voting control. Readers are cautioned that the foregoing list is not exhaustive.

Parallel and Ceres undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

U.S. Disclaimer

Neither the securities of Ceres nor of Parallel have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered and sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act.

Any securities of either Ceres or Parallel sold in the United States will be “restricted securities” within the meaning of Rule 144 under the U.S. Securities Act. Such securities may be resold, pledged or otherwise transferred only pursuant to an effective registration statement under the U.S. Securities Act or pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act.

Texas CUP License #0006

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.